Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Geron Corporation Stock Is Surging Higher Today

What happened

Shares of Geron Corp. (NASDAQ: GERN  ) gained as much as 21% in pre-market trading today after the clinical-stage biotech announced that a second internal review of imetelstat's ongoing clinical trials for two blood-based malignancies  -- lower risk myelodysplastic syndromes (MDS) and relapsed or refractory myelofibrosis (MF) -- warrants further investigation for both indications. Johnson & Johnson's (NYSE: JNJ  ) biotech subsidiary Janssen is handling the drug's clinical program through a collaborative license with Geron. 

A rocket in the sky

Image source: Getty Images.

So what

After imetelstat's first internal data review, its utility in myelofibrosis appeared to be in serious doubt. Janssen, after all, closed patient enrollment in the 4.7 mg/kg dosing arm of the study, and only detected an "encouraging trend" in the higher 9.4 mg/kg dosing arm. 

Today, however, the two companies reported that the second internal review supported the 9.4 mg/kg as an appropriate starting dose for patients with relapsed or refractory MF. While short on details, the good news is that imelstat appears to be providing a clinical benefit in MF worthy of additional investment by J&J and Janssen. 

Now what

Imetelstat's study in MF will reportedly continue unchanged, keeping the hope alive that this drug will ultimately garner multiple indications in the high-value hematology space. If so, it should turn out to be a blockbuster product. 

Additionally, J&J and Geron said that the second part of imetelstat's other trial in MDS will be submitted for refinements to the FDA. And if all goes according to plan, imetelstat could be in the pivotal phase of its trial for MDS by the fourth quarter of this year. 

The key takeaway is that imetelstat is starting to look like the real deal. So, while it's probably prudent to remain cautious with this small-cap biotech, it might be a good idea to start grabbing at least a few shares in case imetelstat does beat the odds and somehow lives up to the lofty expectations of J&J and Geron.  

10 stocks we like better than Geron
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Geron wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 3, 2017

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4012616, ~/Articles/ArticleHandler.aspx, 4/29/2017 1:27:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
Change down DOW 20940.5 -40.8 -0.2%
Change down S&P 500 2384.2 -4.6 -0.2%
Change down NASD 6047.6 -1.3 0.0%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/28/2017 4:00 PM
GERN $2.56 Down -0.07 -2.66%
Geron CAPS Rating: ***
JNJ $123.47 Down -0.27 -0.22%
Johnson & Johnson CAPS Rating: *****

Article registration testing

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 21402687146293824643947422678178